Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Robert S. who wrote (22979)	7/9/1998 11:14:00 AM
From: Henry Niman	Respond to of 32384

Robert, The new drug will have to go through the FDA approval process. However, the clinical trial time may be somewhat shortened because the safety and efficacy of the parent compound will have been established. The requirement for the development of resistance is really not an issue. LGND is already working on second generation compounds in areas that have generated first generation compounds. For instance Targretin is in trials for cancer here and abroad and is in trials for diabetes in Europe. However, introduction of LGD1268 or LGD1324 into the clinic here is expected soon (at the Phase I level for diabetes) while Targretin is expected to enter diabetes trials here soon (at the Phase II level).